Abbott’s capital expenditures of approximately $1.1 billion in 2017, 2016 and 2015 were principally for upgrading and expanding manufacturing and research and development facilities and equipment in various segments, investments in information technology, and laboratory instruments placed with customers. Abbott’s core laboratory diagnostics business offers informatics and automation solutions to increase efficiency in laboratories, and in 2017 continued the international roll-out of its Alinity integrated family of next-generation diagnostic systems and solutions designed to increase efficiency by running more tests in less space, generating test results faster and minimizing human errors while continuing to provide quality results. Within cardiovascular and neuromodulation, research and development programs include enhancements to assist systems with enhanced connectivity, user-interfaces and remote patient monitoring, reflecting an emphasis on technology resources and connectivity to support business needs.